Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingNov 27, 2024Vitamin D3cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.Safecor Health, LLC · D-0056-2025Class IIOngoingNov 27, 2024XelstrymDefective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).Noven Pharmaceuticals Inc · D-0055-2025Class IITerminatedNov 27, 2024Ramipril Capsules USP 10 mgCGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendorLupin Pharmaceuticals Inc. · D-0054-2025Class IITerminatedNov 27, 2024Ramipril Capsules USP 5 mgCGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendorLupin Pharmaceuticals Inc. · D-0053-2025Class IITerminatedNov 27, 2024Ramipril Capsules USP 2.5 mgCGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendorLupin Pharmaceuticals Inc. · D-0052-2025Class IITerminatedNov 27, 2024BEVACIZUMABLack of Sterility AssuranceTailstorm Health INC · D-0051-2025Class IITerminatedNov 27, 2024Guaifenesin Dextromethorphan SyrupFailed Impurity/Degradation SpecificationsThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0050-2025Class IITerminatedNov 27, 2024Guaifenesin Dextromethorphan SyrupFailed Impurity/Degradation SpecificationsThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0049-2025Class IIITerminatedNov 27, 2024Triamcinolone Acetonide Cream USPSubpotent and Superpotent Drug. Out of specification assay results recorded as part of Uniformity of Container test during long-term stability testing.Padagis US LLC · D-0048-2025Class IIIOngoingNov 27, 2024IBU (ibuprofen) 600 mg tabletsFailed Tablet/Capsule SpecificationsDr. Reddy's Laboratories, Inc. · D-0047-2025Class IIOngoingNov 20, 2024Perio Maintenance Rinse 0.63% Stannous Fluoride Concentrated SolutionSubpotent DrugKeystone Industries · D-0046-2025Class IIITerminatedNov 20, 2024Hydralazine HCl TabletsFailed Impurities/Degradation Specifications; during routine stability testing for impurities.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0045-2025Class IIOngoingNov 20, 2024Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.Cipla USA, Inc. · D-0044-2025Class IIOngoingNov 20, 2024Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.Cipla USA, Inc. · D-0043-2025Class IIOngoingNov 20, 2024Trinity Gold NutritionMarketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared acetaminophen, diclofenac and phenylbutazone.Trinity Gold Nutrition · D-0042-2025Class IIOngoingNov 13, 2024Ibuprofen 800mgFailed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.Direct Rx · D-0041-2025Class ITerminatedNov 13, 2024Ascorbic Acid Inj. SolutionPresence of Particulate Matter: Presence of glass particulates.Staska Pharmaceuticals, Inc. · D-0040-2025Class IIOngoingNov 13, 2024Regadenoson InjectionLabeling: Missing LabelBaxter Healthcare Corporation · D-0039-2025Class IIOngoingNov 13, 2024Dapsone Gel 7.5%CrystallizationViona Pharmaceuticals Inc · D-0038-2025Class IIOngoingNov 13, 2024Morphine Sulfate Extended-Release Tablets 30 mgFailed Impurities/Degradation SpecificationDr. Reddy's Laboratories, Inc. · D-0037-2025Class IIOngoingNov 13, 2024Morphine Sulfate Extended-Release Tablets 15 mgFailed Impurities/Degradation SpecificationDr. Reddy's Laboratories, Inc. · D-0036-2025Class IIOngoingNov 13, 2024Timolol Maleate Ophthalmic Solution USPDefective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottleFDC Limited · D-0035-2025Class IIIOngoingNov 13, 2024Kids' Cough and Chest CongestionCrystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.Denison Pharmaceuticals, LLC · D-0034-2025Class IIIOngoingNov 13, 2024Adult Cough and Chest CongestionCrystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.Denison Pharmaceuticals, LLC · D-0033-2025Class IITerminatedNov 6, 2024Cinacalcet TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Accord Healthcare, Inc. · D-0032-2025Class IITerminatedNov 6, 2024Cinacalcet TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Accord Healthcare, Inc. · D-0031-2025Class IITerminatedNov 6, 2024Cinacalcet Tablets 30 mgCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Accord Healthcare, Inc. · D-0030-2025Class IITerminatedNov 6, 2024Chlorpheniramine Maleate 4 mg tabletsSuperpotent Drug: Stability failure for assay at 6 months test time-point.BLI International, Inc. · D-0029-2025Class IIOngoingNov 6, 2024Cinacalcet TabletsCGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limitDr. Reddy's Laboratories, Inc. · D-0028-2025Class IIOngoingNov 6, 2024Cinacalcet TabletsCGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limitDr. Reddy's Laboratories, Inc. · D-0027-2025Class IIOngoingNov 6, 2024Cinacalcet TabletsCGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limitDr. Reddy's Laboratories, Inc. · D-0026-2025Class IIOngoingOct 30, 2024OneLAX Docusate Sodium LiquidCGMP DeviationsAkron Pharma, Inc. · D-0025-2025Class IIOngoingOct 30, 2024AK Forte Ortiga y Omega 3 Cont. Neto 100 TabletasMarketed without an Approved NDA/ANDA: FDA analysis found the product to be tainted with undeclared diclofenac and acetaminophen.C & A Naturistics · D-0024-2025Class IITerminatedOct 30, 2024Thiamine HCl 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0023-2025Class IITerminatedOct 30, 2024EPINEPHrine 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0022-2025Class IITerminatedOct 30, 2024Oxytocin 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0021-2025Class IITerminatedOct 30, 2024NORepinephrine Bitartrate 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0020-2025Class IITerminatedOct 30, 2024NORepinephrine Bitartrate 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0019-2025Class IITerminatedOct 30, 2024Vancomycin HCl 750 mg per 250 mL 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0018-2025Class IITerminatedOct 30, 2024Phenylephrine HCl 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0017-2025

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.